Depsipeptides and drugs containing the same as the active ingredient
CA 2259159 A1 · Owner: Takasu, Masako · Inventors: Kinoshita, Nobuhiro; Oshida, Norio; Yasuda, Orie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Depsipeptides represented by general formula (1) or pharmacologically acceptable salts thereof, wherein R1 represents linear or branched C5-20 alkyl or linear or branched C5-15 alcoxymethyl; R2 represents -A-B -A-B-W, -A-B-W-D , or -A-B-W-D-E; and R3 represents hydroxy lower alkoxy, benzyloxy, -Z, -Z-G or , -Z-G-J wherein A, B, D, E, G and J independently represent each an amino acid residue selected from among alanine, valine leucine, isoleucine, serine, threonine lysine, hydroxylysine, arginine, cysteine methionine, phenylalanine, tyrosine, aspartic acid asparagine, glutamic acid, glutamine, etc. optionally bonded to N-(C1-4 alkyl); W and Z independently represent each an animo acid …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 25, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 25, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 25, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.